Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality

Schulz, Stefanie; Kastrati, Adnan
March 2013
European Heart Journal;Mar2013, Vol. 34 Issue 12, p872
Academic Journal
No abstract available.


Related Articles

  • Optimal Duration of Clopidogrel Use after Implantation of Drug-Eluting Stents � Still in Doubt. Berger, Peter B. // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, p1441 

    The author reflects on whether stent thrombosis is a result of the use of drug-eluting stents and the required duration of dual antiplatelet therapy after implantation of drug-eluting stents. He explains the relationship between stent thrombosis and large myocardial infarction or death. The...

  • CARDIOVASCULAR. Ha, Tina // Journal of Pharmacy Practice & Research;Mar2014, Vol. 44 Issue 1, p48 

    The article presents several cardiovascular abstracts including the optimal duration of dual anti-platelet therapy after drug-eluting stent (DES) implantation, anemia in chronic heart failure (CHF), and myocardial infraction without coronary artery disease (CAD).

  • The Latest on Bleeding. Garrett, Anna D. // Drug Topics;Oct2016, Vol. 160 Issue 10, p36 

    The article focuses on the optimal length of dual antiplatelet therapy and the role of platelet transfusion for serious gastrointestinal (GI) bleeding in patients taking antiplatelet medication. A review of 11 randomized controlled trials including 33,051 patients sought to clarify questions...

  • DAPT study expands to seven EU countries.  // Medical Device Daily;5/27/2010, Vol. 14 Issue 102, p2 

    The article focuses on the expansion of the dual antiplatelet therapy (DAPT) study to include participation from the Czech Republic, France, Germany, Hungary, Poland, Romania and Great Britain. The four-year clinical trial that investigates the duration of DAPT after the implantation of...

  • Extended DAPT after stenting increases risk of bleeding.  // Reactions Weekly;Jun2015, Vol. 1554 Issue 1, p8 

    An abstract of the article "Longer Versus Shorter Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis," by F. A. Spencer and colleagues is presented.

  • Clinicians receive some support to tweak stent-related antiplatelet therapy. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;12/15/2013, Vol. 70 Issue 24, p2164 

    The article presents the Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) study. It looks into the viability of shortening of dual antiplatelet therapy after drug-eluting stent (DES) implantation. It...

  • Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen. Jämbor, C.; Spannagl, M.; Zwissler, B. // Anaesthesist;Oct2009, Vol. 58 Issue 10, p971 

    In patients with coronary stents scheduled for surgery the question arises whether and how antiplatelet therapy should be continued. Risks of perioperative bleeding and of acute stent thrombosis have to be considered simultaneously. The bleeding risk depends primarily on the kind of surgery and...

  • Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Grines, Cindy L.; Bonow, Robert O.; Casey Jr, Donald E.; Gardner, Timothy J.; Lockhart, Peter B.; Moliterno, David J.; O'Gara, Patrick; Whitlow, Patrick // Journal of the American Dental Association (JADA);May2007, Vol. 138 Issue 5, p652 

    The article warns against premature discontinuation of dual antiplatelet therapy after coronary stenting. According to the authors, discontinuation of antiplatelet therapy greatly increases the risk of stent thrombosis, myocardial infarction and death. The authors stress the importance of 12...

  • No Change in Thrombotic Risk With Short-Term DAPT After Stenting. Parry, Nicola // MD Conference Express;Dec2013, p21 

    The article focuses on the Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice trial (OPTIMIZE) regarding the safety and clinical impact of drug-eluting stent (DES) in treating coronary hear disease. The randomized...

  • Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder. Yi-Sik Kim; Sang-Rok Lee // Texas Heart Institute Journal;Oct2015, Vol. 42 Issue 5, p483 

    Stent thrombosis is a life-threatening sequela of drug-eluting stent implantation. Dual anti-platelet therapy with aspirin and thienopyridine is typically used to prevent this catastrophic event. In terms of stent thrombosis, the major concern is the variable response of patients to clopidogrel,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics